Larimar Therapeutics (LRMR) Change in Account Payables (2013 - 2025)
Larimar Therapeutics (LRMR) posted Change in Account Payables of -$5.8 million for Q4 2025, down 184.5% on a QoQ basis from $6.9 million in Q3 2025, and down 890.38% year-over-year from $738000.0 in Q4 2024.
Larimar Therapeutics (LRMR) Change in Account Payables (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Change in Account Payables history runs 13 years deep, the most recent figure standing at -$5.8 million for Q4 2025.
- Quarterly Change in Account Payables fell 890.38% year-over-year to -$5.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 144.7% YoY) and the FY2025 annual result came in at $2.8 million, up 144.7% from the prior year.
- Change in Account Payables was -$5.8 million for Q4 2025 at Larimar Therapeutics, down from $6.9 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $6.9 million in Q3 2025 and bottomed at -$5.8 million in Q4 2025.
- A 5-year average of $129100.0 and a median of $435500.0 in 2022 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables surged 1045.36% — and 2025, when it sank 890.38%.
- Larimar Therapeutics' Change in Account Payables stood at -$97000.0 in 2021, then jumped by 1045.36% to $917000.0 in 2022, then plunged by 42.53% to $527000.0 in 2023, then jumped by 40.04% to $738000.0 in 2024, then sank by 890.38% to -$5.8 million in 2025.
- Business Quant data shows LRMR's Change in Account Payables at -$5.8 million in Q4 2025, $6.9 million in Q3 2025, and $1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 16.86 Mn |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | -5.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.83 Mn |
| Dec 31, 2025 | -5.83 Mn |
| Sep 30, 2025 | 6.90 Mn |
| Sep 30, 2025 | 6.90 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | -150,000.00 |
| Mar 31, 2025 | -150,000.00 |
| Dec 31, 2024 | 738,000.00 |
| Dec 31, 2024 | 738,000.00 |
| Sep 30, 2024 | -1.22 Mn |
| Sep 30, 2024 | -1.22 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | 290,000.00 |
| Mar 31, 2024 | 290,000.00 |
| Dec 31, 2023 | 527,000.00 |
| Dec 31, 2023 | 527,000.00 |
| Sep 30, 2023 | -1.59 Mn |
| Sep 30, 2023 | -1.59 Mn |